- Oral presentation
- Open Access
Stress CMR myocardial perfusion imaging (CMR-MPI) is cost-effective compared to nuclear SPECT: a retrospective cost-effectiveness analysis
© Francis et al; licensee BioMed Central Ltd. 2012
- Published: 1 February 2012
- Percutaneous Coronary Intervention
- Cardiac Event
- Myocardial Perfusion Imaging
- Framingham Heart Study
- Repeat Stress
Stress CMR myocardial perfusion is a strong risk-stratifying tool increasingly used for patient management. However, the cost-effectiveness of this technique in patients with suspected ischemia, has never been studied against nuclear SPECT.
From 2003-2011, 707 patients underwent CMR-MPI for ischemia assessment in our center. Estimated pre-test cardiac risk derived from a combined Framingham Heart Study and Diamond Forrester risk percentage was used to match CMR patients against 39,876 patients who underwent pharmacologic stress SPECT in another tertiary-care center during the same time period. Framingham scoring system for the prediction of cardiovascular risk was also stratified by presence or absence of prior evidence of CAD. A validated computer algorithm was used to perform 1:1 patient risk-matching. For all patients, cardiac events (acute MI/death), angiographically-significant CAD, percutaneous coronary intervention and bypass grafting, repeat stress testing/imaging within 2 years, and cost estimates for these events from national average were collected for cost-effectiveness analysis.
CMR-MPI Negative or equivocal for Ischemia
SPECT Negative or equivocal for Ischemia
Cardiac Event Rate (%/2 years)
Need for Repeat Imaging within 2 years
Need for coronary angiography within 2 years
PCI or Bypass Surgery Performed within 2 years
Estimated Cost of SPECT or CMR-MPI (N=705)
Estimated Costs of Related Patient Care over 2-yrs ($)
In patients with an intermediate risk of ischemic heart disease, stress CMR myocardial perfusion is cost-effective when compared to pharmacologic stress SPECT. A negative stress CMR perfusion study is associated with a lower 2 year event rate and lower downstream costs.
Dr. Kwong is in part supported by the National Institutes of Health R01HL091157. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.